Sermorelin vs HGH comes down to signal versus hormone. Sermorelin is a lab-made fragment of growth hormone-releasing hormone that prompts the pituitary gland to release its own growth hormone. HGH, or somatropin, is the finished hormone itself. HGH has an FDA label and federal distribution limits. Compounded sermorelin is not FDA-approved, and its adult trial evidence in the sources here is one small 1997 study of a closely related analog.

Key takeaways

Sermorelin vs HGH: side-by-side comparison

Sermorelin and HGH differ on four layers: what they are, how the body regulates them, how the law treats them and how much evidence stands behind them. The table puts those layers next to each other.

LayerSermorelinHGH (somatropin)
What it isAnalog of GHRH(1-29), built from the first 29 amino acids of GHRH (Sinha et al.)Recombinant human growth hormone; initial U.S. approval 1987 (DailyMed)
Where it actsUpstream, on the pituitaryDirectly, as the hormone itself
Relationship to feedbackRelease still runs through the body's own regulation (a mechanism argument, per an editorial)Injected dose enters circulation outside normal feedback (Walker, 2006)
FDA statusCompounded, not FDA-approved; brand Geref was approved and later discontinuedFDA-approved biologic under a Biologics License Application
Approved adult useNo current FDA-approved indicationReplacement of growth hormone in adults with growth hormone deficiency
Distribution rulesPrescription medication, prescribed by a licensed clinician if appropriateFederal law limits distribution to uses authorized by HHS (Perls et al., 2005)
Adult evidence baseOne small 1997 trial (19 people) of a modified analogFDA label plus systematic reviews in healthy adults
Safety informationNo current FDA labelDetailed label contraindications and warnings

This is an educational comparison, not a recommendation. Not everyone is a candidate for either drug, and appropriateness is a clinical decision.

Is sermorelin a form of growth hormone?

No. Sermorelin is a fragment of growth hormone-releasing hormone (GHRH), the messenger that tells the pituitary to release growth hormone. It is not growth hormone itself.

GHRH is made in the hypothalamus, a region at the base of the brain. It acts on the pituitary, a small gland just below it. A narrative review describes sermorelin as the "prototypical" growth hormone secretagogue, meaning a substance that prompts growth hormone release. The review says it acts on the hypothalamic-pituitary-somatotropic axis, unlike secretagogues that work through the ghrelin pathway (Sinha et al., Transl Androl Urol). A 2006 editorial identifies it chemically as GRF 1-29 NH2-acetate (Walker, Clin Interv Aging, 2006).

Somatropin is the drug name for recombinant human growth hormone. Recombinant means it is produced by engineered cells rather than extracted from human tissue.

The practical consequence is simple. Sermorelin can only work if the pituitary is able to respond to the signal. HGH skips that step. For a broader explainer on this class of therapy, see sermorelin for adults and how GHRH peptide therapy works.

Does the feedback loop make sermorelin safer?

Not provably. The feedback loop is a sound physiological reason to expect sermorelin to behave differently from injected HGH, but it is a mechanism, not a measured safety outcome. None of the sources here includes a trial comparing sermorelin with HGH on clinical outcomes.

Here is the physiology. The body releases growth hormone in pulses and has built-in brakes, chiefly somatostatin, a hormone that tells the pituitary to stop releasing it. A releasing-hormone signal still answers to those brakes. Injected HGH adds growth hormone to the bloodstream regardless of what the pituitary is doing. Walker's editorial describes a bolus HGH injection as a "square wave" exposure that normal feedback does not control (Walker, 2006).

Walker argued that this makes sermorelin a potentially better approach to growth hormone replacement in aging. He noted that routine HGH use in age management was controversial because few studies had examined long-term risks. He also acknowledged that those concerns were speculative until enough evidence accumulated. That framing is honest, and it cuts both ways. Many clinic pages present the feedback loop as proof that sermorelin is safer. It is a hypothesis worth taking seriously, not a result.

The hormone response in the 1997 trial also changed over time. In that small trial of a modified GHRH(1-29) analog, IGF-1 rose within two weeks, stayed elevated through week 12 and returned toward baseline by week 16 in both men and women (Khorram et al., JCEM, 1997). IGF-1 (insulin-like growth factor 1) is made mainly in the liver in response to growth hormone and is used as a blood marker of its activity. Its binding protein, IGFBP-3, followed the same pattern. The trial data cited here do not establish whether participants were still receiving the analog at week 16, so they cannot show whether the effect faded during treatment.

Why is HGH so tightly regulated?

HGH is restricted by a federal distribution rule, not by controlled-substance scheduling. Under the Federal Food, Drug, and Cosmetic Act (FDCA), growth hormone may be distributed only for uses authorized by the Secretary of Health and Human Services (HHS), and anti-aging is not one of them.

Most prescription drugs can legally be prescribed off-label, meaning for uses not listed on the label. Growth hormone is an exception. A 2005 JAMA commentary laid out the rule and quoted an FDA letter on penalties under section 303 of the FDCA: up to five years in prison, or ten if the offense involves a minor (Perls et al., JAMA, 2005). The commentary adds three points:

It is a commentary, not a trial, and two of its authors were defendants in a lawsuit brought by an anti-aging medicine organization.

The DEA's role feeds a common myth. Many pages call HGH a controlled substance. It is not federally scheduled. The FDA label listing for Norditropin, one somatropin product, shows "DEA Schedule: None" (Norditropin label, DailyMed, 2025). The restriction comes from the FDCA distribution rule.

The label's approved uses are pediatric growth conditions and, in adults, replacement of growth hormone in adults with growth hormone deficiency. The pediatric conditions include inadequate GH secretion, Turner syndrome, Noonan syndrome, Prader-Willi syndrome, idiopathic short stature, and being born small for gestational age without catch-up growth. Anti-aging, athletic performance and body composition in healthy adults are not labeled uses.

The rule described in the commentary is specific to growth hormone. Sermorelin is a different drug, but it is still a prescription medication. If prescribed, it is prepared by a state-licensed 503A compounding pharmacy or an FDA-registered 503B outsourcing facility. "Research use only" peptide sellers are a separate and riskier category. Here is how to tell a legitimate peptide provider from a research-chemical site.

What the adult research shows for each

HGH has systematic-review evidence in healthy adults, and that evidence does not support HGH as an anti-aging therapy. Sermorelin-type evidence in adults, in the sources here, is one small 1997 trial of a related analog that reported hormone levels rather than clinical outcomes.

StudyTypeWho was studiedWhat it found
HGH in healthy older adults (Liu et al., 2007)Systematic review of randomized trials18 study populations; 220 GH-treated completers; mean age 69Fat mass down about 2.1 kg, lean mass up about 2.1 kg, weight unchanged; more adverse events
HGH and athletic performance (Liu et al., 2008)Systematic review of 44 trialsGH-treated vs untreated participantsMore soft tissue swelling, joint pain and carpal tunnel syndrome; efficacy and safety poorly understood
Modified GHRH(1-29) analog (Khorram et al., 1997)Small placebo-controlled trial19 healthy adults aged 55 to 71Higher nocturnal GH vs placebo; IGF-1 rose, then returned toward baseline by week 16

The 2007 review's authors called the body-composition changes small, reported increased rates of adverse events and concluded that GH cannot be recommended as an anti-aging therapy. They also noted that most included studies had small samples. An independent appraisal called it a generally well-conducted review with appropriately cautious conclusions.

The 1997 trial is the sermorelin-type study in the verified sources here. A later review describes it as single-blind, randomized and placebo-controlled (Sinha et al.). It also has clear limits:

  1. Small sample: 19 participants.
  2. Limited follow-up, with IGF-1 back toward baseline by week 16; the data cited here do not establish whether treatment was still ongoing then.
  3. Decades old.
  4. It tested a modified analog, [Nle27]GHRH(1-29)-NH2, not today's compounded sermorelin.
  5. It measured hormone levels and body composition, not clinical outcomes such as function or disease events.

The verified sources here include no large randomized outcome trial of sermorelin in adults.

One rule follows from all of this. HGH trial results, good or bad, cannot be assumed to apply to sermorelin. And a single small trial of a related analog cannot be scaled up into HGH-sized promises. For a graded summary, see the sermorelin evidence summary.

Sermorelin side effects vs HGH

HGH's risks are well characterized because it has been studied and labeled extensively. Sermorelin's risks are less characterized because it has been studied less, which is not the same as being lower.

The Norditropin label lists these contraindications: active malignancy, acute critical illness, hypersensitivity, and active proliferative or severe non-proliferative diabetic retinopathy (DailyMed). Its warnings relevant to adults include:

Common adverse reactions on the label include headache, edema, joint pain, paresthesia (tingling), muscle pain, flu syndrome and impaired glucose tolerance. The 2008 review found the same pattern of swelling, joint pain and carpal tunnel syndrome in healthy GH-treated participants (Liu et al., 2008).

Compounded sermorelin has no current FDA label, and its adult safety record in the sources here comes from one small 1997 trial of a related analog. That trial monitored routine safety blood tests, but it is a small dataset. As a general point, injected peptides can cause injection-site reactions. Before deciding whether sermorelin is appropriate, a licensed clinician reviews your health history, including any cancer history and other conditions.

Why compounded sermorelin is not FDA-approved

Sermorelin prescribed today is compounded, and compounded medications are not FDA-approved. Geref, the brand version of sermorelin, was FDA-approved and later discontinued.

Compounded medications are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities. Compounded sermorelin shares an active ingredient with the discontinued brand, but it is not equivalent to Geref and it is not a form of HGH. The FDA has not reviewed a compounded product's safety and effectiveness for a specific use the way it reviews an approved drug. For the full history, see whether sermorelin is FDA-approved and what happened to Geref.

How access works through New Blue

New Blue does not provide HGH. It offers a Sermorelin injectable pathway, and a licensed clinician decides whether it is appropriate for you.

  1. You complete an asynchronous intake covering your health history, medications and goals.
  2. A licensed clinician reviews it. Some treatments or states may require a live visit.
  3. If prescribed, a licensed partner pharmacy ships the medication directly to you. Use follows your clinician's guidance and pharmacy instructions.

Not everyone qualifies. Eligibility depends on your intake and clinical review, and that's how it should work. If treatment isn't appropriate, refunds follow our refund policy. Consultation timing varies by clinician availability.

The pathway is for adults 21 and older and is not for emergencies. Availability varies by state; see state availability. For current pricing, see the Sermorelin injectable treatment page.

New Blue is a technology and administrative services platform. Medical services are provided by independent licensed clinicians; medications are dispensed only if prescribed.

Frequently Asked Questions

Is sermorelin the same as HGH?

No. Sermorelin is a synthetic fragment of growth hormone-releasing hormone that prompts the pituitary to release its own growth hormone. HGH, or somatropin, is recombinant growth hormone itself. Sermorelin depends on a pituitary that can respond, and HGH does not.

Is HGH a controlled substance?

Not under federal law. The FDA label listing for Norditropin, a somatropin product, shows no DEA schedule. HGH is restricted by a federal law that allows distribution only for uses authorized by the HHS Secretary. A 2005 JAMA commentary notes that the DEA can investigate violations of that rule.

Can I get HGH for anti-aging?

Anti-aging is not an authorized use of growth hormone under federal law. A 2005 JAMA commentary describes distribution for it as illegal, with penalties of up to five years in prison. A systematic review in healthy older adults also concluded that GH cannot be recommended as an anti-aging therapy.

Does sermorelin work as well as HGH?

There is no head-to-head evidence in the sources reviewed here, so the two cannot be compared on outcomes. HGH has a detailed FDA label and systematic-review data. Sermorelin-type adult data in these sources come from one small 1997 trial of a related analog that reported hormone levels. Neither drug's results can be transferred to the other.

Is sermorelin FDA-approved today?

No. The brand product Geref was FDA-approved and later discontinued. Sermorelin prescribed today is compounded, and compounded medications are not FDA-approved. It is prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities.

Does New Blue offer HGH?

No. New Blue does not provide HGH. Its pathways include Sermorelin injectable, where a licensed clinician reviews an asynchronous intake and decides whether treatment is appropriate. Some treatments or states may require a live visit.

Sources

  1. NORDITROPIN (somatropin) injection, for subcutaneous use - Prescribing Information. U.S. National Library of Medicine, DailyMed (FDA label; Novo Nordisk), 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1058e17c-9261-459c-a3e6-fae38d196c14
  2. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Annals of Internal Medicine, 2007. https://pubmed.ncbi.nlm.nih.gov/17227934/
  3. Systematic Review: The Effects of Growth Hormone on Athletic Performance. Annals of Internal Medicine, 2008. https://doi.org/10.7326/0003-4819-148-10-200805200-00215
  4. Provision or distribution of growth hormone for "antiaging": clinical and legal issues. JAMA, 2005. https://pubmed.ncbi.nlm.nih.gov/16249424/
  5. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 2006. https://pmc.ncbi.nlm.nih.gov/articles/PMC2699646/
  6. Endocrine and Metabolic Effects of Long-Term Administration of [Nle27]Growth Hormone-Releasing Hormone-(1–29)-NH2 in Age-Advanced Men and Women. The Journal of Clinical Endocrinology & Metabolism, 1997. https://doi.org/10.1210/jcem.82.5.3943
  7. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology (Sinha et al.), narrative review. https://tau.amegroups.org/article/view/33160/28655

Medical disclaimer: This article is for educational purposes only and is not medical advice. Treatment decisions, including whether any medication is appropriate for you, are made by a licensed clinician based on your intake and clinical review. New Blue Health is a technology and administrative services platform, not a medical provider.

Related treatment guide

Related reading

Content review & editorial standards

This page is educational content from the New Blue Health Editorial Team. It is checked under the New Blue Health Content Review Policy and Editorial Policy and should not replace individualized medical advice from a licensed clinician. For how we evaluate evidence, see Evidence Methodology and Clinical Sources & References.

Start Your Visit